Phase II PARAMOUNT trial of LCZ696
| Autor: | Bryony M. Mearns |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Pressure overload
medicine.medical_specialty business.industry medicine.drug_class PARAMOUNT trial Atrial natriuretic peptide Internal medicine cardiovascular system Cardiology Natriuretic peptide Medicine In patient cardiovascular diseases Cardiology and Cardiovascular Medicine business Heart failure with preserved ejection fraction Neprilysin hormones hormone substitutes and hormone antagonists circulatory and respiratory physiology |
| Zdroj: | Nature reviews. Cardiology. 9(11) |
| ISSN: | 1759-5010 |
| Popis: | As the PARAMOUNT investigators explain in their report published in the Lancet, “atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) ... act to defend the heart from volume and pressure overload, a protective mechanism recently shown to be deficient early in the development of heart failure with preserved ejection fraction (HFpEF).” Solomon et al. therefore set out to test whether inhibition of neprilysin, which degrades ANP and BNP (but not NT-pro-BNP), would augment this protective mechanism and be beneficial in patients with HFpEF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|